Frontiers in Immunology (May 2019)
Immune Correlates of Disease Progression in Linked HIV-1 Infection
- Michael Tuen,
- Jude S. Bimela,
- Jude S. Bimela,
- Andrew N. Banin,
- Andrew N. Banin,
- Shilei Ding,
- Shilei Ding,
- Gordon W. Harkins,
- Svenja Weiss,
- Vincenza Itri,
- Allison R. Durham,
- Stephen F. Porcella,
- Sonal Soni,
- Luzia Mayr,
- Josephine Meli,
- Josephine Meli,
- Judith N. Torimiro,
- Judith N. Torimiro,
- Marcel Tongo,
- Marcel Tongo,
- Xiaohong Wang,
- Xiang-Peng Kong,
- Arthur Nádas,
- Daniel E. Kaufmann,
- Daniel E. Kaufmann,
- Daniel E. Kaufmann,
- Zabrina L. Brumme,
- Zabrina L. Brumme,
- Aubin J. Nanfack,
- Aubin J. Nanfack,
- Aubin J. Nanfack,
- Thomas C. Quinn,
- Thomas C. Quinn,
- Susan Zolla-Pazner,
- Andrew D. Redd,
- Andrew D. Redd,
- Andrés Finzi,
- Andrés Finzi,
- Andrés Finzi,
- Miroslaw K. Gorny,
- Phillipe N. Nyambi,
- Phillipe N. Nyambi,
- Ralf Duerr
Affiliations
- Michael Tuen
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Jude S. Bimela
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Jude S. Bimela
- Department of Biochemistry, University of Yaoundé 1, Yaoundé, Cameroon
- Andrew N. Banin
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Andrew N. Banin
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
- Shilei Ding
- Centre de Recherche du CHUM, Montréal, QC, Canada
- Shilei Ding
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC, Canada
- Gordon W. Harkins
- South African MRC Bioinformatics Unit, South African National Bioinformatics Institute, University of the Western Cape, Bellville, South Africa
- Svenja Weiss
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Vincenza Itri
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Allison R. Durham
- Division of Intramural Research, National Institutes of Health-National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
- Stephen F. Porcella
- Genomics Unit, Research Technologies Branch, Division of Intramural Research, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, United States
- Sonal Soni
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Luzia Mayr
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Josephine Meli
- 0Medical Diagnostic Center, Yaoundé, Cameroon
- Josephine Meli
- 1Yaoundé General Hospital, Yaoundé, Cameroon
- Judith N. Torimiro
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
- Judith N. Torimiro
- 2“Chantal Biya” International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon
- Marcel Tongo
- 3Center of Research for Emerging and Re-Emerging Diseases, Institute of Medical Research and Study of Medicinal Plants, Yaoundé, Cameroon
- Marcel Tongo
- 4School of Laboratory Medicine and Medical Sciences, Nelson R. Mandela School of Medicine, KwaZulu-Natal Research Innovation and Sequencing Platform, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
- Xiaohong Wang
- 5Veterans Affairs New York Harbor Healthcare Systems, New York, NY, United States
- Xiang-Peng Kong
- 6Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, United States
- Arthur Nádas
- 7New York University School of Medicine, Institute of Environmental Medicine, New York, NY, United States
- Daniel E. Kaufmann
- Centre de Recherche du CHUM, Montréal, QC, Canada
- Daniel E. Kaufmann
- 8Department of Medicine, Université de Montréal, Montréal, QC, Canada
- Daniel E. Kaufmann
- 9Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, United States
- Zabrina L. Brumme
- 0Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Zabrina L. Brumme
- 1British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada
- Aubin J. Nanfack
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Aubin J. Nanfack
- 0Medical Diagnostic Center, Yaoundé, Cameroon
- Aubin J. Nanfack
- 2“Chantal Biya” International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon
- Thomas C. Quinn
- Division of Intramural Research, National Institutes of Health-National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
- Thomas C. Quinn
- 2Department of Medicine, Johns Hopkins University, Baltimore, MD, United States
- Susan Zolla-Pazner
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Andrew D. Redd
- Division of Intramural Research, National Institutes of Health-National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
- Andrew D. Redd
- 2Department of Medicine, Johns Hopkins University, Baltimore, MD, United States
- Andrés Finzi
- Centre de Recherche du CHUM, Montréal, QC, Canada
- Andrés Finzi
- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC, Canada
- Andrés Finzi
- 3Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada
- Miroslaw K. Gorny
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Phillipe N. Nyambi
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- Phillipe N. Nyambi
- 5Veterans Affairs New York Harbor Healthcare Systems, New York, NY, United States
- Ralf Duerr
- Department of Pathology, New York University School of Medicine, New York, NY, United States
- DOI
- https://doi.org/10.3389/fimmu.2019.01062
- Journal volume & issue
-
Vol. 10
Abstract
Genetic and immunologic analyses of epidemiologically-linked HIV transmission enable insights into the impact of immune responses on clinical outcomes. Human vaccine trials and animal studies of HIV-1 infection have suggested immune correlates of protection; however, their role in natural infection in terms of protection from disease progression is mostly unknown. Four HIV-1+ Cameroonian individuals, three of them epidemiologically-linked in a polygamous heterosexual relationship and one incidence-matched case, were studied over 15 years for heterologous and cross-neutralizing antibody responses, antibody binding, IgA/IgG levels, antibody-dependent cellular cytotoxicity (ADCC) against cells expressing wild-type or CD4-bound Env, viral evolution, Env epitopes, and host factors including HLA-I alleles. Despite viral infection with related strains, the members of the transmission cluster experienced contrasting clinical outcomes including cases of rapid progression and long-term non-progression in the absence of strongly protective HLA-I or CCR5Δ32 alleles. Slower progression and higher CD4/CD8 ratios were associated with enhanced IgG antibody binding to native Env and stronger V1V2 antibody binding responses in the presence of viruses with residue K169 in V2. ADCC against cells expressing Env in the CD4-bound conformation in combination with low Env-specific IgA/IgG ratios correlated with better clinical outcome. This data set highlights for the first time that V1V2-directed antibody responses and ADCC against cells expressing open, CD4-exposed Env, in the presence of low plasma IgA/IgG ratios, can correlate with clinical outcome in natural infection. These parameters are comparable to the major correlates of protection, identified post-hoc in the RV144 vaccine trial; thus, they may also modulate the rate of clinical progression once infected. The findings illustrate the potential of immune correlate analysis in natural infection to guide vaccine development.
Keywords
- human immunodeficiency virus (HIV)
- epidemiologically-linked infection
- BEAST
- ADCC
- IgA/IgG ratio
- V1V2 antibody binding